Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Case report

Hydroxychloroquine/lopinavir/ritonavir

Lack of efficacy and off label use: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Lee JE, et al. Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study. Antiviral Therapy 26: 34-42, No. 1-2, 2 Sep 2021. Available from: URL: http://doi.org/10.1177/13596535211039394 Lee JE, et al. Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study. Antiviral Therapy 26: 34-42, No. 1-2, 2 Sep 2021. Available from: URL: http://​doi.​org/​10.​1177/​1359653521103939​4
Metadaten
Titel
Hydroxychloroquine/lopinavir/ritonavir
Lack of efficacy and off label use: 3 case reports
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-16002-8

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Tacrolimus

Case report

Tozinameran

Case report

Penicillamine

Case report

Adenosine